Chordia Therapeutics

Executive Summary

Chordia Therapeutics is a Japanese biotechnology company pioneering the development of selective small molecule inhibitors against challenging kinase and signaling targets in oncology and immunology. Founded in 2017 and based in Fujisawa, Japan, the company employs structure-based drug design to create precision medicines targeting CLK, MALT1, CDK12, and GCN2. These targets are central to cancer proliferation and immune dysregulation, offering potential in both monotherapy and combination regimens. Chordia's pipeline is in early clinical stages, with a focus on addressing high unmet need indications such as hematologic malignancies and solid tumors. The company's approach is distinguished by its ability to target previously undruggable kinases with high selectivity, which could lead to improved efficacy and reduced off-target toxicity. With a lean team of 10-50 employees, Chordia represents an agile player in the competitive landscape of targeted cancer therapies. Its proprietary platform and deep expertise in kinase biology position it well for future growth, though the company remains private and has not disclosed significant funding rounds. The success of its lead programs in Phase 1 trials will be critical for validation and potential partnership opportunities.

Upcoming Catalysts (preview)

• TBDPhase 1 Data Readout for Lead CLK Inhibitor50% success
• TBDIND Filing for MALT1 Inhibitor Program70% success
• TBDPotential Partnership or Licensing Deal for CDK12 Program40% success